Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced

Nitish K. Dhingra,Subodh Verma,Javed Butler,Stefan D. Anker,Joao Pedro Ferreira,Gerasimos Filippatos,James L. Januzzi,Carolyn S.P. Lam,Naveed Sattar,Liliana Zaremba-Pechmann,Michael Böhm,Matias Nordaby,Martina Brueckmann,Stuart J. Pocock,Faiez Zannad,Milton Packer

JACC. Heart failure（2024）

引用 1|浏览50

暂无评分

摘要

Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977).

查看译文

关键词

diuretic agents,empagliflozin,heart failure with reduced ejection fraction

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要